A measurement of the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy may allow for better matching of patients to the optimal intensity of chemotherapy.
Current research indicates that a rare but aggressive subtype of pediatric acute lymphoblastic leukemia (ALL) has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene.
Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.
Breastfeeding a child may reduce that child's risk of developing pediatric acute lymphoblastic leukemia (ALL).
Presence of this protein indicates a likely toxicity effect associated with chemotherapy in acute myeloid leukemia (AML).
Children with acute lymphoblastic leukemia with a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study.
A tenth of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase inhibitor ibrutinib because of disease progression during clinical trials, according to a study.
An increase in genetic mutations that could trigger leukemia seems to be a part of aging, according to a new study, but just having cancer-linked DNA doesn't mean the disease will develop.
A previously unrecognized action as a potent inhibitor of the dominant mutation that confers drug resistance to all well-tolerated treatments in patients with certain leukemia types has been found in Axitinib.
Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemiaFebruary 27, 2015
About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.
A subset of antiviral immune cells could prevent CMV infections in bone marrow transplant recipientsFebruary 24, 2015
A small subset of antiviral immune cells may be enough to fight and even prevent the disease caused by cytomegalovirus (CMV) in patients that receive bone marrow transplants.
Young adult survivors of leukemia and lymphoma are more likely to report high stress compared with older survivors of the same diseases.
The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.
A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.
According to results of a new, retrospective study, the risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer is double that previously reported.
An oral targeted agent has shown encouraging activity and limited side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research.
Patients with advanced leukemia, when treated with a new type of cancer therapy that blocks mutated IDH2 protein, showed dramatic results in a clinical trial.
Pediatric patients with acute lymphoblastic leukemia (ALL) showed a 90% response rate from the first trials testing an investigational personalized cellular therapy known as CTL019.
Among early-stage breast cancer patients who undergo chemotherapy and/or radiation treatment, the risk for developing treatment-related leukemia, though low, is still double what experts had previously thought.
The drug, which spurs the body's immune system, has now been approved to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (ALL).
For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent diseaseOctober 28, 2014
Obese pediatric patients with acute lymphoblastic leukemia (ALL) are more likely to have minimal residual disease.
For younger patients with an acute lymphoblastic leukemia (ALL) subtype, modifying treatment based on chemotherapy response can make a vital difference.
Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.
Tyrosine kinase inhibitors (TKIs) may be effective for the treatment of acute lymphoblastic leukemia (ALL).
Many young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and could benefit from drugs used to treat other types of leukemia.
Weekend hospital admission for pediatric patients with newly diagnosed leukemia is associated with a longer length of stay, slightly longer wait to start chemotherapy, and higher risk for respiratory failure.
CPI-613 safe and somewhat efficacious for the treatment of patients with relapsed or refractory leukemia.
A select team of immune-system cells from patients with leukemia can be multiplied in the laboratory, creating a horde of natural killer cells that can be used to target and destroy the cancer cells.
By analyzing the DNA sequence of patients at different stages of leukemia, researchers have discovered mutations in genes that lead to childhood leukemia of the acute lymphoblastic type, the most common childhood cancer.
Weekend admission for pediatric patients with leukemia associated with a longer length of stay.
- Vitamin D and prostate cancer: Higher intake improves active surveillance outcomes
- Triple combination of two targeted therapies + immunotherapy is more effective in advanced melanoma
- Muscle-building supplements may be associated with testicular cancer
- Promising drug target identified in medulloblastoma
- Physical activity associated with less chemo-induced peripheral neuropathy
- mHealth app assesses breast cancer risk and aids prevention
- Socioeconomic factors increase mortality after lung cancer surgery
- Half of older U.S. adults take aspirin as preventive medicine
- Cardiorespiratory fitness linked with decreased metabolic syndrome risk among smokers
- Adjuvant chemotherapy in non-small cell lung cancer: State-of-the-art
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|